Natera (NASDAQ:NTRA) Insider Sells $220,548.48 in Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 928 shares of the company’s stock in a transaction that occurred on Wednesday, January 28th. The stock was sold at an average price of $237.66, for a total value of $220,548.48. Following the sale, the insider owned 175,540 shares of the company’s stock, valued at $41,718,836.40. This trade represents a 0.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

John Fesko also recently made the following trade(s):

• On Tuesday, January 27th, John Fesko sold 784 shares of Natera stock. The shares were sold at an average price of $240.53, for a total transaction of $188,575.52.
• On Wednesday, January 21st, John Fesko sold 339 shares of Natera stock. The shares were sold at an average price of $235.00, for a total transaction of $79,665.00.
• On Tuesday, January 20th, John Fesko sold 17,806 shares of Natera stock. The stock was sold at an average price of $234.74, for a total transaction of $4,179,780.44.

Natera Stock Down 0.1%

Shares of NASDAQ:NTRA opened at $231.14 on Friday. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36. The firm’s 50-day simple moving average is $235.91 and its 200-day simple moving average is $194.11. The company has a market cap of $31.97 billion, a price-to-earnings ratio of -100.93 and a beta of 1.62.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. During the same quarter in the previous year, the business earned ($0.26) EPS. Natera’s revenue for the quarter was up 34.7% on a year-over-year basis. On average, research analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of recent analyst reports. Citigroup initiated coverage on shares of Natera in a research note on Wednesday, January 7th. They set a “buy” rating and a $300.00 price target on the stock. Stephens upped their target price on shares of Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Guggenheim increased their target price on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a report on Monday, January 5th. Morgan Stanley boosted their price target on Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Finally, Piper Sandler upped their price target on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average target price of $249.20.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Horizon Investments LLC acquired a new position in shares of Natera in the third quarter worth $32,000. Hilltop National Bank acquired a new position in Natera in the 2nd quarter valued at about $33,000. Sound Income Strategies LLC lifted its holdings in Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 110 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new position in Natera in the 4th quarter valued at about $41,000. Finally, Quent Capital LLC acquired a new stake in shares of Natera during the 3rd quarter worth about $46,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced completion of enrollment in the randomized ACES‑EMB heart‑transplant trial — a clinical milestone for the transplant franchise (Prospera) that de‑risks the program’s pathway to clinical readouts and potential uptake. Article Title
• Positive Sentiment: Wall Street coverage remains largely favorable: multiple firms maintain buy/outperform views and several have raised targets (MarketBeat summary shows consensus around a “Moderate Buy” and an average target near $249). This supports upside expectations if results and growth continue.
• Neutral Sentiment: Natera reported preliminary Q4 revenue (details in the alert). Preliminary figures may influence sentiment when the final quarter report and guidance are released; investors should watch the formal Q4 release for confirmation versus consensus. Preliminary Q4 Revenue
• Neutral Sentiment: Institutional ownership remains extremely high (~99.9%), which tends to stabilize the shareholder base but can also concentrate selling/Buying flows when large holders move. (Source: MarketBeat summary.) Institutional Data
• Negative Sentiment: Multiple insider sales by senior executives: CFO Michael Burkes Brophy sold several tranches (totaling 5,064 shares across Jan. 20–29) and CEO Steven Chapman sold several thousand shares (roughly 5,970 shares across Jan. 27–28). These trades total millions of dollars and may create short‑term selling pressure despite insiders retaining large residual stakes. CFO Form 4 CEO Form 4
• Negative Sentiment: Other insiders (John Fesko, Solomon Moshkevich) also sold smaller tranches. While each reduction is under ~1% of those insiders’ holdings, the cluster of sales amplifies negative signaling to the market. Fesko Form 4 Moshkevich Form 4

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.